Cascadian Therapeutics, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Medical Specialties
TMOThermo Fisher Scientific, Inc. -0.36%480.271.0%$539.93m
ABTAbbott Laboratories -1.53%107.810.8%$513.96m
DHRDanaher Corp. -0.52%232.770.7%$492.46m
MDTMedtronic Plc -0.38%111.420.6%$454.97m
ALGNAlign Technology, Inc. 3.60%469.566.4%$392.73m
ISRGIntuitive Surgical, Inc. 0.35%735.482.3%$390.03m
BSXBoston Scientific Corp. 0.81%37.161.0%$330.07m
DXCMDexCom, Inc. 3.84%411.007.9%$310.21m
BDXBecton, Dickinson & Co. -0.29%240.401.0%$273.84m
QDELQuidel Corp. 1.01%248.217.7%$218.44m
BAXBaxter International, Inc. -0.43%81.101.8%$204.00m
SYKStryker Corp. -1.15%222.061.3%$202.55m
VARVarian Medical Systems, Inc. 0.48%172.569.1%$189.77m
EWEdwards Lifesciences Corp. 1.30%80.410.4%$183.32m
IDXXIDEXX Laboratories, Inc. 1.43%429.663.8%$138.89m

Company Profile

Cascadian Therapeutics, a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States. The company lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It is also developing Checkpoint kinase 1, a protein kinase that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress. In addition, the company focuses on the development of novel antibodies and T-cell immunoreceptor with Ig and ITM domains, an inhibitory receptor expressed on T-cells and NK cells that negatively regulate immune response to cancers. It has a license agreement with Array BioPharma Inc. to develop, manufacture and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against d immunotherapy targets in oncology.